ARCHIVES

FDA Official Outlines agency’s Views On Efficacy Requirement

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

In Brief: Muggia Leaving NCI For NYU In September; Seminar Planned On radiation Exposures

April 20, 1979

Nexavar Improves PFS In Phase III Trial

January 25, 2013

NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement

June 26, 1987

Army Plans Solicitation For Breast Cancer Research Proposals

April 21, 1995

Intensity Modulated Therapy Safer Than Three-Dimensional Radiation

June 24, 2011

Hematologic Malignancies: ASCO Meeting Highlights New Approaches To Treatment

July 30, 2004